Breaking Finance News

BTIG Research announced Kite Pharma (NDAQ:KITE), boosting its stock price target to $100.00 today

In a report released on 6/08/2017 BTIG Research increased the stock price target of Kite Pharma (NDAQ:KITE) to $100.00 reporting a possible upside of 0.15%.

Previously on 05/10/2017, Canaccord Genuity released a statement about Kite Pharma (NDAQ:KITE) increased the target price from $0.00 to $90.00. At the time, this indicated a possible upside of 0.21%.

Just yesterday Kite Pharma (NDAQ:KITE) traded 0.00% even at $86.89. Kite Pharma’s 50-day moving average is $175.64 and its 200-day moving average is $113.31. The last stock price is down 58.68% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has increased 0.03% over the same time period. 100 shares of KITE traded hands, down from an average trading volume of 2,005,000

Recent Performance Chart

Kite Pharma (NDAQ:KITE)

Kite Pharma has 52 week low of $39.82 and a 52 week high of $179.95 and has a market capitalization of $0.

In addition to BTIG Research reporting its stock price target, a total of 11 brokerages have issued a ratings update on the company. The average stock price target is $74.18 with 6 brokerages rating the stock a strong buy, 7 brokerages rating the stock a buy, 0 brokerages rating the stock a hold, 0 brokerages rating the stock a underperform, and finally 0 brokerages rating the stock a sell.

Brief Synopsis On Kite Pharma (NDAQ:KITE)

Kite Pharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products to target and kill cancer cells. The Company offers engineered autologous cell therapy, which is an approach to the treatment of cancer. Its therapy involves modifying a patient's T cells outside the patient's body, or ex vivo, causing the T cells to express chimeric antigen receptors (CARs), or T cell receptors (TCRs), and then reinfusing the engineered T cells back into the patient. Its lead product candidate, KTE-C19, is a CAR-based therapy that targets the CD19 antigen, a protein expressed on the cell surface of B-cell lymphomas and leukemias. The Company is conducting a registrational Phase II clinical trial (ZUMA-1) of KTE-C19 in patients with relapsed or refractory aggressive diffuse large B cell lymphoma (DLBCL), primary mediastinal B cell lymphoma (PMBCL), or transformed follicular lymphoma (TFL).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.